# Agent B Critique — Round 03 Evaluation

## Agent A (cursor/open-source-release-audit-aed5)

### Strengths

- **Complete adoption and alignment.** Agent A's round 03 is the definitive convergence — it adopts the 19-issue scope, 3-category branding framework, release contract question, sanitize-not-delete for CLAUDE.md, and the full blocker set. Declaring "no disagreements" is fully credible at this point.
- **Practical and concise.** The plan is immediately executable. The changes section maps directly to issue files with clear actions per item.
- **Correct license precision.** Consistently specifies server and shared (not client) for missing license metadata.

### Weaknesses

- **Fewer open questions than Agents B and C.** Six questions vs ten each. Missing items like trufflehog scan, transitive license attestation, runbook publication controls, and pre-release dependency scan ownership are genuinely useful.
- **No explicit exit criteria in the plan text.** Both Agent B and Agent C include verification criteria per phase. Agent A's plan describes what to do but not how to verify it's done correctly.

### Errors

- No factual errors.

---

## Agent C (cursor/open-source-release-audit-b07b)

### Strengths

- **Major convergence: CLAUDE.md operational identifiers elevated to BLOCKER.** This was the sole remaining disagreement from round 02. Agent C's creation of `BLOCKER-sensitive-operational-identifiers-in-public-runbooks.md` resolves it — operational identifiers (App IDs, Installation IDs, Modal secret names) are now recognized as a Day 0 fix by all three agents.
- **Best separation of internal doc categories.** Agent C now explicitly tracks operational identifiers (BLOCKER) separately from planning artifacts like PRD.md/tasks.md (IMPORTANT). This mirrors my approach of separate issue files and is the most precise treatment.
- **Most comprehensive open questions.** 10 questions including unique additions: runbook publication controls (Q9, ensuring future CLAUDE.md edits stay clean) and pre-release dependency scan ownership (Q10, assigning accountability). Both are practically important.
- **New valid findings.** Added `IMPORTANT-print-statement-in-production-tracker-job.md` and `IMPORTANT-run-one-time-dependency-vulnerability-audit-before-release.md` — both already in my inventory but now independently confirmed.

### Weaknesses

- **Stated disagreements are largely resolved in practice.** Agent C lists 5 disagreements, but most are no longer substantive:
  - #1 (`.env.example` as IMPORTANT) — all agents agree
  - #2 (branding not a blanket blocker) — addressed by the 3-category framework all agents use
  - #4 (distinct remediation paths) — already implemented via separate issue files in my audit
  - #5 (phase discipline) — addressed by sequencing with exit criteria
  - Only #3 (CONTRIBUTING/CODE_OF_CONDUCT as IMPORTANT vs CRITICAL) represents a real remaining difference
- **Listing resolved items as "disagreements" creates a false impression of divergence.** At this stage, explicitly noting which prior disagreements have been resolved would better reflect the actual state.

### Errors

- No factual errors.

---

## Agent B (my own — cursor/oss-release-audit-98a0)

### Strengths

- **Most complete execution plan with exit criteria.** Day 0 and Week 1 phases have specific verification steps. This was adopted from Agent C's feedback and represents the most actionable format.
- **19 issues validated across three rounds.** Zero false positives, zero remaining factual corrections. Every finding independently confirmed by at least one other agent.
- **Sole remaining disagreement now resolved.** Agent C's round 03 elevation of CLAUDE.md operational identifiers to BLOCKER means all three agents agree on the core blocker set for the first time.

### Weaknesses

- **Could explicitly acknowledge the CLAUDE.md convergence.** My round 03 solution was written before seeing Agent C's round 03 elevation to BLOCKER. In retrospect, I should note that the sole stated disagreement from round 02 is now moot.

### Errors

- No factual errors.

---

## My Position

### Keeping

1. **19-issue inventory with remediation sequencing and exit criteria.** This is the converged final state across all agents.
2. **Six blockers.** Now unanimously agreed (Agent C's round 03 elevated operational identifiers to BLOCKER, resolving the last disagreement).
3. **Release contract as the top-level strategic question.** All agents include this.
4. **Sanitize-not-delete for CLAUDE.md.** Unanimous consensus.

### Adopting from others

1. **Agent C's Q9 (runbook publication controls)** — ensuring future CLAUDE.md edits stay clean is a process gap worth tracking.
2. **Agent C's Q10 (pre-release dependency scan ownership)** — assigning accountability for the one-time audit is practically useful.

### Still disagree on

1. **CONTRIBUTING/CODE_OF_CONDUCT severity (Agent C: IMPORTANT vs Agent B: CRITICAL).** This is the only remaining substantive difference. I classify community docs as CRITICAL (Week 1) because launching without any contributor guidance creates a poor first impression for the first external contributors who arrive. Agent C classifies as IMPORTANT (deferrable). This is genuinely a judgment call — both positions are defensible.
